SCHEMBL2910124

SCHEMBL2910124

CCCC(C)c1ccccc1NC(=S)NC(=O)c1cc2c(Cl)nccc2o1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 9/20 0.45
NPC1 O15118 8/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 2/20 0.41
KCNH2 Q12809 1/20 0.41
TP53 P04637 1/20 0.41
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
P2RX4 Q99571 1/20 0.37
P2RX7 Q99572 1/20 0.37
P2RX2 Q9UBL9 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2914220 0.85 POLB (0.46) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL2911448 0.82 ALDH1A1 (0.51) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL2918332 0.80 ALDH1A1 (0.51) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL2942288 0.79 ALDH1A1 (0.45) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL2916508 0.79 POLB (0.44) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL5839890 0.78 ALDH1A1 (0.49) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL4366064 0.75 NPC1 (0.46) ALDH1A1HTTRAB9ANPC1L3MBTL1
SCHEMBL14018574 0.75 SIRT2 (0.46) ALDH1A1HTTRAB9ANPC1TP53
SCHEMBL13175613 0.73 MAPT (0.48) ALDH1A1HTTRAB9ANPC1POLB
SCHEMBL2914954 0.71 ALDH1A1 (0.46) ALDH1A1HTTRAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP claimed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US claimed
JP-2007517887-A 2007-07-05 JP claimed
EP-1709047-A2 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2006-10-11 EP claimed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US claimed
WO-2005067900-A2 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2005-07-28 WO claimed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication NAT1, PIGS, ADORA1 ALDH1A1 171/4885HTT 1410/4885RAB9A 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.